查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477346

基因分型檢測市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品和服務、技術、應用、最終用戶、地區和競爭細分，2019-2029F

Genotyping Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Technology, By Application, By End User, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球基因分型檢測市場估值為 154.6 億美元，到 2029 年，預測期內將以 14.86% 的複合年成長率實現令人印象深刻的成長。基因分型測定是一種實驗室技術，用於識別個體 DNA 中特定基因組位置的遺傳變異。它提供了對這些位置的核苷酸序列的深入了解，包括單核苷酸多態性 (SNP)、插入、缺失和拷貝數變異 (CNV)。例如，微陣列平台採用固定在固體表面上的 DNA 探針來同時分析數千至數百萬個遺傳變異。 DNA 樣本在微陣列上進行雜交，螢光訊號有助於確定每個基因組位置的基因型。另一方面，等位基因特異性 PCR 檢測透過設計用於選擇性擴增感興趣的等位基因的引子來針對不同的 SNP 變體。利用序列互補性，等位基因特異性 PCR 能夠精確檢測 DNA 樣本中的特定基因型。基因分型測定有廣泛的應用，涵蓋生物醫學研究、臨床診斷、個人化醫療、農業和法醫學。它們有助於疾病遺傳學的探索、藥物反應標記的識別、遺傳多樣性的評估以及育種計劃的加強。

市場概況
預測期 2025-2029
2023 年市場規模 154.6億美元
2029 年市場規模 355.8億美元
2024-2029 年複合年成長率 14.86%
成長最快的細分市場 毛細管電泳
最大的市場 北美洲

基因分型技術的持續創新，包括新一代定序 (NGS)、基於微陣列的基因分型、聚合酶鍊式反應 (PCR) 和毛細管電泳，推動了市場擴張。這些進步促進了高通量、準確且具成本效益的基因分型測定，擴大了其在研究、診斷和個人化醫療領域的實用性。全球遺傳性疾病、慢性病和傳染病的盛行率不斷上升，凸顯了疾病診斷、預後和治療中對基因分型測定的需求不斷增加。在農業和動物基因組學領域，基因分型測定在育種計畫、性狀選擇、抗病分析和牲畜管理中發揮關鍵作用。對高產作物、抗病植物和優質牲畜品種的追求推動了這些領域的市場成長。因此，基因分型檢測成為推動各產業和學科進步不可或缺的工具。

主要市場促進因素

基因分型技術的進步

遺傳性疾病和慢性病的發生率不斷增加

在農業和動物基因組學中的不斷成長的應用

主要市場挑戰

數據解釋與分析的複雜性

標準化和品質控制

主要市場趨勢

擴大採用 SNP（單核苷酸多態性）基因分型

細分市場洞察

技術洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球基因分型檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務（試劑和試劑盒、基因分型服務、儀器、定序儀和放大器、分析儀、生物資訊學、軟體、服務）
    • 依技術（PCR、微陣列、定序、毛細管電泳、MALDI-TOF 等）
    • 按應用（藥物基因組學、診斷和個人化醫療、農業生物技術、動物遺傳學、其他應用）
    • 按最終用戶（製藥和生物製藥公司、診斷和研究實驗室、學術機構等）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美基因分型檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 依技術
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲基因分型檢測市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 依技術
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區基因分型檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 依技術
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲基因分型檢測市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 依技術
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲基因分型檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 依技術
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • Agilent Technologies Inc.
  • Danaher Corporation
  • Hoffmann-La Roche Ltd.
  • GE Healthcare Technologies Inc.
  • Standard BioTools Inc.
  • Eurofins Scientific SE
  • Bio-Rad Laboratories Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23971

Global Genotyping Assay Market was valued at USD 15.46 billion in 2023 and will see an impressive growth in the forecast period at a CAGR of 14.86% through2029. A genotyping assay is a laboratory technique utilized to identify genetic variations within an individual's DNA at specific genomic locations. It furnishes insights into nucleotide sequences at these positions, encompassing single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs). Microarray platforms, for instance, employ DNA probes immobilized on a solid surface to concurrently analyze thousands to millions of genetic variants. DNA samples undergo hybridization onto the microarray, with fluorescent signals aiding in genotype determination for each genomic position. Allele-specific PCR assays, on the other hand, target distinct SNP variants via primers designed to selectively amplify the allele of interest. Leveraging sequence complementarity, allele-specific PCR enables the precise detection of specific genotypes within DNA samples. Genotyping assays boast diverse applications spanning biomedical research, clinical diagnostics, personalized medicine, agriculture, and forensic science. They facilitate the exploration of disease genetics, identification of drug response markers, assessment of genetic diversity, and enhancement of breeding programs.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 15.46 Billion
Market Size 2029USD 35.58 Billion
CAGR 2024-202914.86%
Fastest Growing SegmentCapillary Electrophoresis
Largest MarketNorth America

Ongoing innovations in genotyping technologies, including next-generation sequencing (NGS), microarray-based genotyping, polymerase chain reaction (PCR), and capillary electrophoresis, propel market expansion. These advancements facilitate high-throughput, accurate, and cost-effective genotyping assays, broadening their utility across research, diagnostics, and personalized medicine domains. The increasing prevalence of genetic disorders, chronic diseases, and infectious ailments globally underscores the heightened demand for genotyping assays in disease diagnosis, prognosis, and treatment. In the agricultural and animal genomics sectors, genotyping assays play pivotal roles in breeding programs, trait selection, disease resistance profiling, and livestock management. The quest for high-yielding crops, disease-resistant plants, and superior livestock breeds fuels market growth in these domains. As such, genotyping assays emerge as indispensable tools driving advancements across various industries and disciplines.

Key Market Drivers

Advancements in Genotyping Technologies

NGS technologies, also termed high-throughput sequencing, facilitate the rapid sequencing of millions of DNA fragments concurrently. These platforms have substantially decreased the time and cost associated with whole-genome sequencing, exome sequencing, and targeted sequencing, rendering genomic analysis more accessible and cost-effective. Microarray technology enables the simultaneous analysis of numerous genetic variants in a single experiment, commonly employed for GWAS, gene expression profiling, copy number variation analysis, and DNA methylation analysis. Digital PCR offers a highly sensitive and precise method for nucleic acid quantification. Unlike conventional PCR, dPCR segregates a sample into thousands of individual reactions, enabling absolute quantification of target DNA or RNA molecules. This technique is valuable for detecting rare mutations, copy number variations, and gene expression levels with exceptional accuracy. Capillary electrophoresis separates and analyzes DNA fragments based on their size and charge, boasting high resolution, sensitivity, and throughput, making it suitable for genotyping applications like SNP analysis, microsatellite genotyping, and fragment length analysis.

Massively Parallel Sequencing (MPS), also termed third-generation sequencing, allows for the simultaneous sequencing of thousands of DNA molecules in real-time. MPS technologies, such as PacBio and Oxford Nanopore sequencing, offer extended read lengths and single molecule sequencing capabilities, ideal for tasks like de novo genome assembly, structural variant detection, and epigenetic analysis. CRISPR-Based Genotyping technology has revolutionized genome editing and genotyping, enabling precise and efficient manipulation of DNA sequences. CRISPR-based genotyping methods enable targeted detection of specific genetic variants and mutations, including allele-specific PCR and high-resolution melting analysis. Multiplex PCR assays simultaneously amplify multiple target DNA sequences in a single reaction, reducing sample input requirements, reaction volumes, and assay time, while increasing throughput and cost-effectiveness. Commonly used for genotyping SNPs, short tandem repeats (STRs), and pathogen detection, multiplex PCR contributes to the development of the Global Genotyping Assay Market.

Increasing Incidence of Genetic Disorders and Chronic Diseases

Genotyping assays play a pivotal role in the early detection and diagnosis of genetic disorders and chronic diseases. By pinpointing specific genetic variants linked to disease susceptibility, progression, and severity, these assays empower healthcare providers to diagnose conditions more accurately and at earlier stages. This enables timely interventions and treatment strategies, enhancing patient outcomes. Genetic insights garnered from genotyping assays facilitate precision medicine approaches, tailoring treatments to individual patients based on their genetic profiles and disease characteristics. Understanding how genetic variations influence drug metabolism, efficacy, and toxicity allows healthcare providers to optimize treatment regimens, improving therapeutic outcomes.

Pharmacogenomics, which examines how genes impact an individual's response to drugs, heavily relies on genotyping assays. By scrutinizing genetic variations related to drug metabolism enzymes, targets, and transporters, pharmacogenomic testing aids healthcare providers in predicting medication responses, refining drug selection and dosing, and minimizing the risk of adverse reactions. Genotyping assays assess genetic risk factors linked to various diseases like cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders. Identifying individuals with heightened risk based on their genetic predispositions enables healthcare providers to implement preventive measures, lifestyle adjustments, and personalized screening protocols, curbing disease incidence and enhancing health outcomes.

In family planning and genetic counseling, genotyping assays provide insights into inherited genetic conditions and disease risks. This empowers individuals and families to make informed decisions about family planning, reproductive options, and prenatal screening, effectively managing their genetic health and reducing the transmission of genetic disorders to future generations. The escalating demand for genotyping assays is fueled by the necessity for robust research tools and platforms to explore the genetic underpinnings of diseases, pinpoint novel therapeutic targets, and develop innovative treatment modalities. These assays are vital in pharmacogenomic investigations, biomarker discovery, and clinical trials, facilitating the advancement of personalized therapies and targeted interventions for genetic disorders and chronic diseases. This factor will accelerate the demand for the Global Genotyping Assay Market.

Growing Applications in Agriculture and Animal Genomics

Genotyping assays play a critical role in agriculture, enhancing crop yield, quality, and resilience to various stresses. By analyzing genetic variations linked to desirable traits like disease resistance and drought tolerance, these assays assist plant breeders in identifying superior parental lines, developing new varieties through marker-assisted selection (MAS), and expediting the breeding process. They aid in trait mapping and marker discovery, allowing researchers to understand complex traits' genetic basis and develop molecular markers for marker-assisted breeding (MAB) programs. Furthermore, genotyping assays offer insights into genetic diversity, population structure, and evolutionary history, assisting in preserving genetic resources and designing effective breeding strategies for sustainable agriculture.

In animal genomics, genotyping assays evaluate disease resistance, susceptibility, and resilience in livestock populations. By identifying genetic markers associated with disease resistance genes, these assays enable selective breeding programs, the development of disease-resistant animal breeds, and enhanced disease management strategies. They support genomic selection and prediction, aiding breeders in identifying superior individuals, predicting trait performance, and optimizing breeding decisions for faster genetic gains. Genotyping assays also ensure quality control and traceability in agricultural supply chains and food production systems. By verifying the genetic identity and authenticity of seed lots, plant varieties, and livestock breeds, they uphold product integrity, regulatory compliance, and consumer confidence in food safety and quality. This aspect will drive the demand for the Global Genotyping Assay Market.

Key Market Challenges

Data Interpretation and Analysis Complexity

Genotyping assays generate vast amounts of genomic data, including genotypic information for numerous genetic variants across multiple samples. Managing, processing, and analyzing such large data volumes require advanced computational infrastructure and bioinformatics expertise. Interpreting genotyping data involves annotating genetic variants with relevant genomic annotations, functional predictions, and clinical significance. Variant annotation and functional analysis require access to comprehensive databases, annotation tools, and knowledge bases, which may pose challenges in data integration and standardization. Analyzing genotyping data involves performing statistical tests, association analyses, and genotype-phenotype correlations to identify significant genetic associations and candidate variants. Statistical analysis methods may vary depending on study design, population structure, and genetic models, requiring expertise in statistical genetics and bioinformatics. Interpreting genotyping data within the biological context of the studied phenotype or disease requires a deep understanding of molecular genetics, cellular pathways, and biological mechanisms. Integrating genotyping data with functional genomics, transcriptomics, and proteomics datasets enhances biological interpretation but may introduce additional complexity. Communicating genotyping results effectively requires data visualization tools and techniques to present complex genomic data in a clear, interpretable format. Generating informative plots, heatmaps, and interactive visualizations facilitates data exploration, hypothesis generation, and result interpretation for researchers and clinicians.

Standardization and Quality Control

Genotyping assays can exhibit variability in experimental conditions, reagents, instrumentation, and data analysis methods, leading to inconsistencies in results across different laboratories and platforms. Standardizing assay protocols and performance metrics is essential to ensure consistency, reliability, and reproducibility of genotyping data. Lack of standardized reference materials and quality control standards poses challenges in assay validation, calibration, and comparison across different genotyping platforms and technologies. Establishing reference materials, certified reference standards, and proficiency testing programs facilitates assay standardization and harmonization, enabling accurate and reliable genotyping results. Maintaining data quality and integrity throughout the genotyping workflow, from sample collection and DNA extraction to data analysis and interpretation, requires robust quality control measures and data validation procedures. Monitoring assay performance, detecting outliers, and implementing data quality checks help identify and mitigate potential sources of error and bias in genotyping data. Inter-laboratory variability in genotyping assays can arise from differences in laboratory practices, equipment calibration, and data analysis pipelines. Collaborative efforts, inter-laboratory comparisons, and proficiency testing programs promote standardization, harmonization, and sharing of best practices among laboratories, enhancing the reliability and comparability of genotyping results. Integrating genotyping data from different platforms, studies, and populations requires harmonization of data formats, quality control metrics, and data annotation standards. Standardized data formats, metadata descriptors, and ontologies facilitate data sharing, meta-analysis, and integration across diverse genotyping datasets, enabling comprehensive genomic research and discovery.

Key Market Trends

Increasing Adoption of SNP (Single Nucleotide Polymorphism) Genotyping

SNP genotyping assays enable the simultaneous analysis of hundreds to thousands of SNPs across the genome in a single experiment. High-throughput SNP genotyping platforms, such as microarrays and next-generation sequencing (NGS), facilitate efficient genotyping of large sample cohorts, accelerating genomic research and discovery. SNP genotyping is widely used in genome-wide association studies (GWAS) to identify genetic variants associated with complex traits, diseases, and phenotypic traits. By analyzing SNP frequencies and allele associations across populations, researchers can pinpoint genomic regions linked to disease susceptibility, drug response, and phenotypic variation. SNP genotyping plays a crucial role in precision medicine by enabling the identification of genetic variations that influence individual responses to drugs, treatments, and environmental factors. Pharmacogenomic testing, which analyzes SNP variants in drug metabolism and drug targets, guides personalized treatment decisions, dosage optimization, and medication selection for improved therapeutic outcomes. SNP genotyping allows for the assessment of genetic risk factors associated with common complex diseases, such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders. By analyzing disease-associated SNPs and polygenic risk scores, healthcare providers can stratify individuals based on their genetic predispositions, implement preventive measures, and offer personalized health interventions to mitigate disease risk. SNP genotyping is valuable for studying population genetics, evolutionary relationships, and genetic diversity across human populations and species. By analyzing SNP variation within and among populations, researchers can reconstruct population histories, infer migration patterns, and unravel evolutionary processes shaping genetic diversity and adaptation in diverse populations.

Segmental Insights

Technology Insights

The Capillary Electrophoresis segment is projected to experience significant growth in the Global Genotyping Assay Market during the forecast period. Capillary electrophoresis (CE) offers high resolution and sensitivity, making it a preferred method for genotyping assays. CE can accurately separate and detect nucleic acids, including DNA fragments and PCR products, based on their size, charge, and mobility, allowing for precise genotyping analysis. Recent advancements in capillary electrophoresis technology have led to the development of automated systems capable of processing large numbers of samples in a high-throughput manner. These automated CE platforms streamline genotyping workflows, improve efficiency, and reduce turnaround times, making them well-suited for applications in research, clinical diagnostics, and drug development. Capillary electrophoresis is a versatile technique that can be adapted to various genotyping assays, including single nucleotide polymorphism (SNP) genotyping, microsatellite analysis, and fragment length analysis. Its flexibility allows researchers and clinicians to customize genotyping assays based on specific research questions, disease markers, or clinical applications. Compared to other genotyping technologies such as next-generation sequencing (NGS) and microarrays, capillary electrophoresis offers a cost-effective solution for medium to high-throughput genotyping applications. The relatively low cost per sample and minimal reagent consumption make CE an attractive option for laboratories with budget constraints or limited resources. Capillary electrophoresis systems are known for their accuracy, reproducibility, and robust performance, ensuring reliable genotyping results across different samples and experimental conditions. The high precision of CE technology makes it suitable for demanding applications in clinical diagnostics, pharmacogenomics, and forensic genotyping.

Application Insights

The Pharmacogenomics segment is projected to experience significant growth in the Global Genotyping Assay Market during the forecast period. There is a growing emphasis on personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic makeup, lifestyle, and other factors. Pharmacogenomics, which studies how genes influence an individual's response to drugs, plays a crucial role in personalized medicine by enabling healthcare providers to optimize drug selection, dosage, and treatment regimens based on patients' genetic profiles. Pharmacogenomics helps healthcare providers identify genetic variations that affect drug metabolism, efficacy, and toxicity. By understanding how individual patients are likely to respond to specific medications, healthcare providers can make more informed treatment decisions, leading to improved therapeutic outcomes, reduced adverse drug reactions, and better patient care. Genotyping assays are increasingly being used in drug development and clinical trials to identify genetic biomarkers associated with drug response and treatment outcomes. Pharmaceutical companies utilize pharmacogenomic data to stratify patient populations, identify potential responders and non-responders to investigational drugs, and optimize clinical trial designs, ultimately accelerating the development and approval of new therapeutics. Technological advancements in genotyping technologies, such as next-generation sequencing (NGS), microarray-based genotyping, and digital PCR, have made it easier and more cost-effective to genotype large numbers of genetic variants accurately and efficiently. These advancements have expanded the scope and scalability of pharmacogenomic studies and enabled widespread adoption of genotyping assays in clinical settings.

Regional Insights

North America emerged as the dominant player in the Global Genotyping Assay Market in 2023. North America, particularly the United States, is at the forefront of technological advancements in genotyping assays. The region is home to leading biotechnology and pharmaceutical companies, academic research institutions, and innovative startups that drive the development and commercialization of cutting-edge genotyping technologies. North America boasts a robust research and development infrastructure, including state-of-the-art laboratories, research centers, and academic institutions with expertise in genomics, molecular biology, and biotechnology. This ecosystem fosters innovation and collaboration, facilitating the rapid advancement and adoption of genotyping assays. The significant investment in healthcare and life sciences research in North America supports the development and commercialization of genotyping assays. Government funding, private investment, and venture capital funding contribute to the growth of the genotyping assay market by providing resources for research, product development, and market expansion..

Key Market Players

Illumina Inc.

Thermo Fisher Scientific Inc.

Qiagen NV

Agilent Technologies Inc.

Danaher Corporation

Hoffmann-La Roche Ltd.

GE HealthCare Technologies Inc.

Standard BioTools Inc.

Eurofins Scientific SE

Bio-Rad Laboratories Inc.

Report Scope:

In this report, the Global Genotyping Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Assay Market, By Product & Service:

    Reagents & Kits Genotyping Services Instruments Sequencers & Amplifiers Analyzers Bioinformatics Software Services

Genotyping Assay Market, By Technology:

    PCR

Real-time PCR

Digital PCR

    Microarrays Sequencing

NGS

Pyrosequencing

Sanger Sequencing

    Capillary Electrophoresis

Amplified Fragment Length Polymorphism

Restricted Fragment Length Polymorphism

Single-stranded Conformation Polymorphism

    MALDI-TOF Others

Genotyping Assay Market, By Application:

    Pharmacogenomics Diagnostic & Personalized Medicine Agricultural Biotechnology Animal Genetics Other Applications

Genotyping Assay Market, By End User:

    Pharmaceutical and Biopharmaceutical Companies Diagnostic and Research Laboratories Academic Institutes Others

Genotyping Assay Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Assay Market.

Available Customizations:

Global Genotyping Assay market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genotyping Assay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Reagents & Kits, Genotyping Services, Instruments, Sequencers & Amplifiers, Analyzers, Bioinformatics, Software, Services)
    • 5.2.2. By Technology (PCR, Microarrays, Sequencing, Capillary Electrophoresis, MALDI-TOF, Others)
      • 5.2.2.1. By PCR (Real-time PCR, Digital PCR)
      • 5.2.2.2. By Sequencing (NGS, Pyrosequencing, Sanger Sequencing)
      • 5.2.2.3. By Capillary Electrophoresis (Amplified Fragment Length Polymorphism, Restricted Fragment Length Polymorphism, Single-stranded Conformation Polymorphism)
    • 5.2.3. By Application (Pharmacogenomics, Diagnostic & Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Other Applications)
    • 5.2.4. By End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America Genotyping Assay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genotyping Assay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Genotyping Assay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Genotyping Assay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Genotyping Assay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genotyping Assay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Genotyping Assay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Genotyping Assay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. France Genotyping Assay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Genotyping Assay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Genotyping Assay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Genotyping Assay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Genotyping Assay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Genotyping Assay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Genotyping Assay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Genotyping Assay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Genotyping Assay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Genotyping Assay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Genotyping Assay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Genotyping Assay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Genotyping Assay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Genotyping Assay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Genotyping Assay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Genotyping Assay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Illumina Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Qiagen NV
  • 14.4. Agilent Technologies Inc.
  • 14.5. Danaher Corporation
  • 14.6. Hoffmann-La Roche Ltd.
  • 14.7. GE Healthcare Technologies Inc.
  • 14.8. Standard BioTools Inc.
  • 14.9. Eurofins Scientific SE
  • 14.10.Bio-Rad Laboratories Inc.

15. Strategic Recommendations

16. About Us & Disclaimer